Bayer's September Legal Verdict Looms Over a Stock Bolstered by Japan Oncology Approval
Published on 08/26/2026 at 03:03 | Redaktion boerse-global.de
The calendar on Bayer's desk has two dates circled, and only one of them carries the weight of a multi-billion-dollar question mark. While the September 14 fairness hearing in Missouri will determine whether the chemicals-to-pharma group can finally close the book on its glyphosate litigation, investors have been handed a fresh reason to look at the operational side of the story: Japan's approval of the company's lung cancer drug in the first-line setting.
The shares have been climbing a wall of cautious optimism in recent weeks. At 49.29 euros, the stock sits roughly 8.5 percent below its 52-week high of 53.86 euros, reached on July 3. Over the past seven trading sessions, the gain amounts to 1.2 percent, extending to 4.2 percent on a 30-day view. Year-to-date, Bayer is up 33 percent, and on a twelve-month horizon the advance stretches to 76 percent. Technical indicators suggest the rally has room to run: the relative strength index reads 57.8, and the price stands 4.2 percent above its 50-day moving average — hardly the profile of an overheated chart.
A Regulatory Win That Widens the Addressable Market
The Japanese approval, granted under the brand name Hyrnuo, marks a notable departure from earlier clearances. Sevabertinib, Bayer's treatment for HER2-mutated non-small cell lung cancer (NSCLC), received accelerated approval from the US FDA in November 2025, followed by a Chinese green light in early 2026 as a monotherapy for patients who had already undergone systemic treatment. Japan goes further: the drug can now be used across all treatment lines, including as a first-line therapy independent of prior treatment history.
That distinction matters commercially. First-line designation significantly expands the pool of eligible patients, giving Bayer's oncology franchise a strategic foothold it lacked in other regions. The approval extends a run of favorable regulatory outcomes across major markets within a matter of months — a welcome counterweight for a company whose agriculture division continues to underperform.
The Balance Sheet Story
The operational backdrop has been firming up as well. Second-quarter results, published in early August, showed group revenue rising 2.2 percent on a currency- and portfolio-adjusted basis to 10.872 billion euros. EBITDA before special items advanced 1.9 percent to 2.144 billion euros, while net profit swung from a loss of 199 million euros in the year-earlier quarter to a gain of 219 million euros. Core earnings per share, however, slipped 16.7 percent to 0.95 euros — a reminder that operational progress and earnings dilution are running in parallel.
Should investors sell immediately? Or is it worth buying Bayer?
The debt picture has improved more decisively. Bayer has trimmed its year-end net financial debt guidance to 29–30 billion euros, down from an earlier range of 32–33 billion euros, reflecting the anticipated 3.0 billion euro capital injection from Apollo-managed funds related to the LARC business. That deal is expected to close in the third quarter of 2026, and its completion would further strengthen a balance sheet already on a downward trajectory.
The September Pivot Point
For all the encouraging headlines, the market's attention is converging on a single procedural event. The fairness hearing for the glyphosate class-action settlement — originally scheduled for August 19 — has been pushed to September 14. The settlement, valued at up to 7.25 billion US dollars and reached in February, has already received preliminary approval. What remains is the final judicial sign-off, a step that is probable but not guaranteed.
The rescheduling itself should not be read as a warning sign; delays of this kind are routine in class-action settlements of this magnitude. The risk lies in the process, not the principle. Fairness hearings can be held up by objections from individual plaintiff groups, formal challenges, or additional requests from the bench. Another postponement would extend the uncertainty surrounding the glyphosate saga, even though the Supreme Court's June 25 ruling — which stripped plaintiffs in warning-label cases of their legal foundation — has shifted the underlying legal terrain in Bayer's favor.
The stakes are straightforward. A final approval would remove a substantial portion of the legal overhang from the company's valuation, allowing the risk premium investors demand for holding the stock to compress further. Combined with the Apollo-driven deleveraging, the operational stabilization at Crop Science, and the confirmed full-year guidance — revenue of 44.7 to 47.0 billion euros and core EPS between 4.10 and 4.80 euros — a green light in September would complete a coherent picture: falling debt, a growing business, and settled litigation.
A failure or further delay would keep the legal cloud intact, leaving a key uncertainty unresolved. The mixed second-quarter performance in pharmaceuticals and consumer health — both segments delivered uneven results — would then remain a standalone drag on the valuation, independent of the courtroom calendar.
Until September 14, the oncology pipeline offers a stream of positive news from a business segment insulated from the agricultural division's legal troubles. The Japan approval is the latest proof that Bayer can still generate regulatory momentum where it matters most. Whether that momentum translates into sustained share-price gains, however, will ultimately be decided in a Missouri courtroom.
Ad
Bayer Stock: New Analysis - 26 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
